Could a single dose of infliximab speed kidney recovery in immunotherapy patients?

NCT ID NCT07683975

First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time

Summary

This study tests whether adding a single dose of infliximab to a short course of prednisone helps people recover kidney function faster after immunotherapy-related acute kidney injury. Participants receive either the combination or standard prednisone alone. The goal is to see if the combination improves recovery rates within 12 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Infliximab and prednisone
What this could lead to
If it works, this could point toward a faster, more effective treatment for immunotherapy-related kidney injury, potentially reducing the need for long-term steroids.
What could go wrong
This is a small pilot study, so results may not be conclusive. Infliximab carries risks like infection and allergic reactions, and the combination may not outperform standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE INTERSTITIAL NEPHRITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Brigham and Women's Hospital

    Boston, Massachusetts, 02115, United States

    Contact Email: •••••@•••••

  • Dana Farber Cancer Institute

    Boston, Massachusetts, 02115, United States

    Contact Email: •••••@•••••

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114, United States

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.